<DOC>
	<DOCNO>NCT00232115</DOCNO>
	<brief_summary>An evaluation safety efficacy calcineurin inhibitor , pimecrolimus cream 1 % , adult patient perioral dermatitis . This study enrol patient United States .</brief_summary>
	<brief_title>Pimecrolimus Cream 1 % Adult Patients With Perioral Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Perioral</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>clinically diagnosed perioral dermatitis associate associated topical steroid use ( periorbital area may also involve addition perioral region ) minimum severity score ( PODSI ) â‰¥ 4 age 18 old Ongoing use follow treatment NOT allow start study drug : Oral tetracycline , oral erythromycin , oral steroid oral calcineurin inhibitor . All topical treatment face , include steroid , calcineurin inhibitor , metronidazole , tetracycline , erythromycin emollient ( exception : DAC Basiscreme ) . Systemic immunosuppression History malignancy organ system , treat untreated , within past 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Perioral Dermatitis , pimecrolimus cream</keyword>
</DOC>